LungLife AI, INC Result of AGM (4930Y)

TIDMLLAI

RNS Number : 4930Y

LungLife AI, INC

04 May 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting , held at earlier today, all 10 resolutions put to members were passed on a poll.

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

 
  Resolution                        Votes for    %        Votes against   %       Votes withheld 
 Resolution 1 ( Common 
  ) 
  TO receive the Annual Report 
  and Accounts of the Company 
  for the year ended 31 December 
  2022 together with the 
  directors' and auditor's 
  reports thereon.                  13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 2 ( Common 
  ) 
  TO approve the Directors' 
  Remuneration Policy.              9,997,926    76.81    3,018,363       23.19   0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 3 ( Common 
  ) 
  TO receive the Directors' 
  Remuneration Report for 
  the year ended 31 December 
  2022.                             13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 4 ( Common 
  ) 
  THAT Roy Davis be, and 
  hereby is, re-elected as 
  a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 5 ( Common 
  ) 
  THAT Paul Pagano be, and 
  hereby is, re-elected as 
  a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 6 ( Common 
  ) 
  THAT David Anderson be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 7 ( Common 
  ) 
  THAT Andrew Boteler be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 8 ( Common 
  ) 
  THAT Sara Barrington be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 9 (Common) 
  THAT James McCullough be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 Resolution 10 ( Common 
  ) 
  THAT Crowe UK LLP be, and 
  hereby is, reappointed 
  as auditor of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   13,016,289   100.00   0               0.00    0 
                                   -----------  -------  --------------  ------  --------------- 
 

The Company notes that, whilst Resolution 2 was passed with the required majority, there was a sizable vote against it representing 23.19% of shareholders who voted. The Company acknowledges these votes and will engage with shareholders to understand further the reasons behind this vote. The Board will provide an update on this engagement and any actions taken will be published within six months of the AGM.

As at 4 May 2023, there were 25,485,982 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

For further information please contact:

 
LungLife AI, Inc.                                                         www.lunglifeai.com 
Paul Pagano, CEO                                                             Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                Tel: [phone] 
 & J oint Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
  Goodbody (Joint Broker)                               Tel: [phone] / +353 (1) 
  Tom Nicholson / Stephen Kane                                                      667 0420 
 
Walbrook PR Limited                    Tel: [phone] or [e-mail] 
Stephanie Cuthbert / Alice Woodings                     Mob: [phone] / 
 / Phillip Marriage                                                            07867 984 082 
 

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com . Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAKSLELPDEFA

(END) Dow Jones Newswires

May 04, 2023 12:49 ET (16:49 GMT)